BioMedNewsBreaks

TuesdaySep 29, 2026 2:55 pm

BioMedNewsBreaks — VERAXA Biotech AG (NASDAQ: VRXA) Moves VXA-222 Bispecific ADC to Next Development Stage

VERAXA Biotech (NASDAQ: VRXA) has advanced its VXA-222 bispecific antibody-drug conjugate (“ADC”) program beyond the initial discovery phase following the completion of its collaboration with OmniAb, with the company now planning to engineer the final candidate using its antibody-engineering, linker and conjugation technologies and conduct in vitro and in vivo preclinical studies. VXA-222 employs an “AND-gate” design intended to recognize two tumor-associated antigens simultaneously, potentially increasing selectivity for cancer cells, while VERAXA continues developing a broader oncology pipeline spanning ADCs, T-cell engagers and other engineered antibody formats. The company has also filed its first patents covering its BiTAC-TCE and BiTAC-ADC…

Continue Reading

TuesdaySep 29, 2026 2:11 pm

BioMedNewsBreaks — Earth Science Tech Inc. (ETST) Adds California Hub to Growing Pharmacy Network

Earth Science Tech (OTC: ETST) recently continued its expansion in the healthcare, pharmacy and telemedicine sectors with the acquisition of Meduvo LLC, a California-based compounding pharmacy operating from a 2,000-square-foot facility in La Verne. The acquisition expands ETST’s pharmacy network to 34 U.S. jurisdictions and gives the company a West Coast operational hub, complementing its existing compounding pharmacy subsidiaries, RxCompoundStore.com and Mister Meds. The company plans to upgrade Meduvo’s facility to meet sterile-compounding requirements, with management targeting regulatory certification by the end of 2028. The acquisition fits ETST’s broader strategy of expanding its geographic reach, integrating telemedicine with pharmacy fulfillment…

Continue Reading

TuesdaySep 29, 2026 9:30 am

BioMedNewsBreaks – Lantern Pharma (NASDAQ: LTRN) Announces $4 Million Registered Direct Offering

Lantern Pharma (NASDAQ: LTRN) announced a definitive agreement for the purchase and sale of 3,669,725 shares of common stock, or pre-funded warrants in lieu thereof, at $1.09 per share in a registered direct offering expected to generate approximately $4 million in gross proceeds. In a concurrent private placement, the company will issue unregistered warrants to purchase up to 3,669,725 additional shares at an exercise price of $1.09 per share, potentially generating approximately $4 million in additional gross proceeds if fully exercised for cash. The offering is expected to close on or about Sept. 30, 2026, subject to customary closing conditions,…

Continue Reading

ThursdaySep 24, 2026 11:52 am

BioMedNewsBreaks – VERAXA Biotech AG (NASDAQ: VRXA) Advances Oncology Pipeline Following Nasdaq Listing as Xlife Sciences (SIX: XLS) Reports First-Half Progress

VERAXA Biotech (NASDAQ: VRXA) is shifting its focus to advancing its oncology pipeline and implementing industrial partnerships for its technology platforms and products following the completion of its business combination and commencement of Nasdaq trading in June 2026. Xlife Sciences AG (SIX: XLS) said VERAXA secured a financing base to support its next development steps and remains an important part of its portfolio strategy. Xlife Sciences also reported operational and scientific progress across its portfolio during the first half of 2026, including developments at x-kidney diagnostics, saniva diagnostics, Axenoll, FUSE-AI and inflamed pharma. The portfolio comprises 416 patents and patent…

Continue Reading

ThursdaySep 24, 2026 9:40 am

BioMedNewsBreaks – Quantum BioPharma Ltd. (NASDAQ: QNTM) Licensee Unbuzzd Wellness Appoints Michael “Zappy” Zapolin CEO

This article has been disseminated on behalf of Quantum BioPharma Ltd. and may include paid advertising. Quantum BioPharma (NASDAQ: QNTM) announced that its licensee, Unbuzzd Wellness Inc., appointed Michael Zapolin as CEO. Zapolin’s mandate includes financing and listing Unbuzzd on a stock exchange, followed by a nationwide commercial marketing and product rollout in the United States. Former CEO Richard Buzbuzian is assisting with the transition to a publicly listed company, which is scheduled to go effective in the next quarter. Unbuzzd markets unbuzzd(TM), a beverage designed to accelerate alcohol metabolism, restore mental clarity and reduce hangover symptoms. The company said…

Continue Reading

WednesdaySep 23, 2026 11:53 am

BioMedNewsBreaks — Onco-Innovations Limited (CBOE CA: ONCO)(OTCQB: ONNVF) (Frankfurt: W1H) (WKN: A3EKSZ) and Redwood AI (CSE: AIRX) (OTCQB: RDWCF) Awarded Digital Health Innovation Fund Grant for AI-Driven Oncology Platform 

This article has been disseminated on behalf of Onco-Innovations Limited and may include paid advertising.  Onco-Innovations (CBOE CA: ONCO) (OTCQB: ONNVF) (Frankfurt: W1H) (WKN: A3EKSZ) and Redwood AI (CSE: AIRX) (OTCQB: RDWCF), together with Canada's Michael Smith Genome Sciences Centre and Centre de recherche du CHU de Québec-Université Laval, were awarded a competitive Digital Health Innovation Fund grant administered by the Terry Fox Research Institute to support development of Onco SynoGraph AI-driven oncology platform. The reimbursement-based grant covers up to 25% of an estimated $3.5 million project budget. The project will advance SynoGraph using federated learning and causal AI to…

Continue Reading

WednesdaySep 23, 2026 9:10 am

BioMedNewsBreaks – Lantern Pharma (NASDAQ: LTRN) to Present Open-Medicine AI Growth Plan, Live Platform Demo in Webinar

Lantern Pharma (NASDAQ: LTRN) will present the growth plan for Open-Medicine AI (“OMAI”), its wholly owned subsidiary developing a multi-agentic AI platform for drug development, during a live webinar today at 12:30 p.m. Eastern. CEO Panna Sharma will lead the 45-minute session, which will cover OMAI market opportunity, customer feedback, platform capabilities, development roadmap, economics, benchmarks, potential partnerships and contribution to shareholder value. OMAI core capabilities and initial platform were developed within Lantern clinical programs and areas of focus. Launched as withZeta.ai in April 2026 with an initial focus on rare cancers, the platform is expanding into additional diseases, therapy…

Continue Reading

TuesdaySep 22, 2026 9:30 am

BioMedNewsBreaks – Lantern Pharma (NASDAQ: LTRN) Receives USPTO Notice of Allowance for LP-284 Blood Cancer Treatment Patent

Lantern Pharma (NASDAQ: LTRN), an AI-driven precision oncology company, announced that the United States Patent and Trademark Office ("USPTO") issued a Notice of Allowance for U.S. Patent Application No. 18/500,032, covering methods of using LP-284 to treat mantle cell lymphoma ("MCL"), double-hit lymphoma ("DHL") and other blood cancers. The allowed claims include LP-284 as a monotherapy and in combination with several classes of anti-cancer agents. Once issued, the patent is expected to extend LP-284 intellectual property protection into 2042, adding method-of-use protection to Lantern existing composition-of-matter patent estate. Lantern Pharma (NASDAQ: LTRN) is evaluating LP-284 in an ongoing Phase 1a…

Continue Reading

FridaySep 18, 2026 3:45 pm

BioMedNewsBreaks — Onco-Innovations Ltd. (CBOE CA: ONCO) (OTCQB: ONNVF) (FSE: W1H) Aligns Manufacturing, Preclinical Work and Clinical Planning for ONC010

Disseminated on behalf of Onco-Innovations Ltd. (CBOE CA: ONCO) (OTCQB: ONNVF) (FSE: W1H) and may include paid advertising. Onco-Innovations (CBOE CA: ONCO)(OTCQB: ONNVF)(FSE: W1H) is advancing its lead preclinical cancer candidate, ONC010, toward potential first-in-human testing by bringing together drug manufacturing, nanoparticle formulation, analytical development, preclinical studies and regulatory planning. ONC010 combines the company’s PNKP-targeting small molecule A83B4C63 with a micellar nanoparticle delivery system intended to enhance drug exposure and tumor accumulation, with the broader strategy focused on disrupting cancer cells’ DNA repair mechanisms and potentially enhancing the effects of radiation and certain chemotherapy treatments. The company has completed a 300-gram development batch of A83B4C63 at approximately…

Continue Reading

FridaySep 18, 2026 3:13 pm

BioMedNewsBreaks — Nano-X Imaging Ltd. (NASDAQ: NNOX) Is Building End-to-End Platform for the Future of Medical Imaging

Nanox (NASDAQ: NNOX) is positioning itself as an integrated medical imaging and healthcare technology company, combining proprietary digital X-ray hardware, FDA-cleared AI applications, cloud software, teleradiology, and healthcare IT into an end-to-end platform designed to support earlier disease detection and more efficient care. Its ecosystem includes Nanox.ARC and the next-generation Nanox.ARC X imaging systems, Nanox.AI algorithms for identifying potential signs of chronic disease, Nanox.CLOUD for imaging management, and services through USARAD, Nanox.MARKETPLACE and Nanox Health IT. The company is expanding commercial and clinical activity through relationships with organizations including RadNet, Cedars-Sinai, Corewell Health and Brigham and Women’s Hospital, while also…

Continue Reading